Why is Fredun Pharma falling/rising?

As of 12-Jun, Fredun Pharmaceuticals Ltd is experiencing a significant rise in its stock price, currently at Rs 801.00, reflecting an increase of Rs 61.0 or 8.24%. The stock has outperformed its sector by 8.34% today and has shown consecutive gains over the last two days, accumulating a total return of 10.48% during this period. Additionally, the stock has reached an intraday high of Rs 820, indicating strong investor interest. The company has reported healthy long-term growth, with net sales increasing at an annual rate of 27.60% and operating profit at 35.06%. Positive results for the last four consecutive quarters, including record net sales and profits, further bolster investor confidence. The stock is also trading at a discount compared to its peers, with a PEG ratio of 0.6, suggesting it may be undervalued.
In the broader market context, Fredun Pharmaceuticals has outperformed the Sensex significantly over the past week and month, with returns of +9.31% and +14.43%, respectively, while the Sensex has only increased by +0.31% and decreased by -0.90%. This strong performance relative to the benchmark indicates a positive sentiment towards the stock amidst a generally stable market environment. The rising investor participation, as evidenced by a 66.57% increase in delivery volume, further supports the notion that investors are increasingly confident in the company's prospects. Overall, the combination of strong financial performance, positive market sentiment, and attractive valuation metrics contributes to the stock's upward movement.